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Abstract
Background and Aim: Histological score systems may not fully capture the essential 
nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of 
screening failure in clinical trials. We assessed the NASH distribution and its compo-
nents across the fibrosis stages and their impact on the prognosis and their relation-
ship with the concept of metabolic- associated fatty liver disease (MAFLD).
Methods: Spanish multicenter study including 1893 biopsy- proven nonalcoholic fatty 
liver disease (NAFLD) patients from HEPAmet registry. NASH was diagnosed by NAS 
score ≥4 (including steatosis, ballooning and lobular inflammation) and fibrosis by 
Kleiner score. The presence of MAFLD was determined. Progression to cirrhosis, first 
episode of decompensated cirrhosis and death were collected during the follow- up 
(4.7 ± 3.8 years).
Results: Fibrosis was F0 34.3% (649/1893), F1 27% (511/1893), F2 16.5% (312/1893), 
F3 15% (284/1893) and F4 7.2% (137/1893). NASH diagnosis 51.9% (982/1893), and 
its individual components (severe steatosis, ballooning and lobular inflammation), in-
creased from F0 (33.6%) to F2 (68.6%), and decreased significantly in F4 patients 
(51.8%) (P = .0001). More than 70% of non- NASH patients showed some inflam-
matory activity (ballooning or lobular inflammation), showing a similar MAFLD rate 
than NASH (96.2% [945/982] vs. 95.2% [535/562]) and significantly higher than non-
alcoholic fatty liver (NAFL) subjects (89.1% [311/349]) (P < .0001). Progression to 
cirrhosis was similar between NASH (9.5% [51/539]) and indeterminate NASH (7.9% 
[25/316]), and higher than steatosis (5% [14/263]) (logRank 8.417; P = .015). Death 
and decompensated cirrhosis were similar between these.
Conclusions: The prevalence of steatohepatitis decreased in advanced liver disease. 
However, most of these patients showed some inflammatory activity histologically 
and had metabolic disturbances. These findings should be considered in clinical trials 
whose main aim is to prevent cirrhosis progression and complications, liver transplant 
and death.
K E Y W O R D S
ballooning, fatty liver disease, inflammation, metabolic- associated fatty liver disease, natural 
coursesteatohepatitis, steatosis
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1  | INTRODUC TION
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of his-
tological features that range from simple steatosis to nonalcoholic 
steatohepatitis (NASH) and, finally, cirrhosis.1 Splitting NAFLD into 
three successive stages (steatosis, non- cirrhotic NASH and cirrhotic 
NASH) has provided a convenient conceptual framework for improv-
ing the diagnostic methods and identifying areas of potential future 
drug development.2 However, the diagnosis of NAFLD is challeng-
ing sometimes, so we need to consider a more pragmatic approach 
to targeting these individuals. In this scenario, the term “metabolic- 
associated fatty liver disease” (MAFLD) has been recently pro-
posed.3 The diagnosis of MAFLD is based on recognizing underlying 
alterations in metabolism,4 beyond the histological classification of 
NAFLD. MAFLD is defined by the presence of steatosis (by histol-
ogy or imaging) and overweight or at least two metabolic risk fac-
tors. Notably, steatosis could be absent in the case of advanced liver 
disease.5
Subjects enrolled in NASH clinical trials are usually required to 
have a NAS ≥ 4 and a fibrosis stage from F1 to cirrhosis by liver bi-
opsy. However, up to half of the screened individuals fail to meet 
these eligibility criteria.6 We should consider that NAS score was 
developed as a tool to measure NAFLD changes during therapeu-
tic trials instead of as a surrogate for the histologic diagnosis of 
NASH.7 Notably, previous studies have reported that 20%– 40% of 
the NAFLD population does not display a definite NASH histolog-
ical diagnosis,8,9 making these individuals ineligible for enrollment. 
Consequently, the large number of suboptimal biopsies adds sig-
nificantly to the cost and duration of clinical trials. However, liver 
fibrosis is considered the strongest predictor of adverse clinical out-
comes.10 Besides, treatment goals for patients with advanced liver 
disease are to halt or slow fibrosis progression, prevent clinical de-
compensation, reduce the need for liver transplantation and improve 
survival.11
The liver biopsy must keep being essential in the management of 
NAFLD,12 but we should avoid converting this tool into a barrier to 
diagnose, treat or identify at- risk patients. For instance, the develop-
ment of non- invasive tests and imaging- based methods has allowed 
a wide expansion of liver fibrosis assessment in at- risk patients.13- 16 
Thus, the liver biopsy should be relocated to maximize its advan-
tages in selected patients. In a Spanish large cohort of individuals 
with biopsy- proven NAFLD followed- up during 4.7 years, we aimed 
to assess the prevalence of NASH and its components (steatosis, 
ballooning and lobular inflammation) across the fibrosis stages and 
link them with prognostic outcomes to determine if NAS score ≥4 
reflects a reliable scenario in clinical practice as inclusion criterium 
in NAFLD clinical trials.
2  | METHODS
2.1 | Selection of patients
This is an observational study of 1893 patients with biopsy- confirmed 
NAFLD who had been enrolled and prospectively followed up from 
the Spanish HEPAmet Registry. This registry is governed by the 
Spanish Association for the Study of the Liver and the Network of 
Biomedical Research Centre for the Study of the Liver and Digestive 
Diseases (CIBERehd). Data monitoring is a fundamental element of 
the registry, ensuring data procurement accuracy and minimization 
of bias.
Patients underwent a liver biopsy according to the routine deci-
sions in the clinical practice (eg, presence of fatty liver by imaging, 
increased aminotransferase levels, based on non- invasive tests and 
suspected advanced liver disease by imaging or laboratory tests) or 
at the time of bariatric surgery. The inclusion criterion was biopsy- 
proven NAFLD, irrespective of the existence of NASH or fibrosis 
stage. Exclusion criteria were significant alcohol intake (≥30 g daily 
for men and ≥20 g daily for women) and evidence of concomitant 
liver disease (ie, viral or autoimmune hepatitis, HIV, drug- induced 
fatty liver, hemochromatosis or Wilson's disease). The study was 
performed in agreement with the Declaration of Helsinki and ap-
proved by the Ethics and Clinical Research Committee of every cen-
tre. All patients were informed of the nature of the study and gave 
their written consent to participate.
2.2 | Clinical assessment
Demographic characteristics, anthropometric measurements and 
laboratory tests (alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), gamma glutamyl transferase (GGT), triglyc-
erides, cholesterol, HDL- c, LDL- c, fasting glucose, HbA1c, insulin, 
creatinine and albumin) were recorded at the same time of liver bi-
opsy. An overnight (12- h) fasting blood sample was taken for rou-
tine biochemical analyses. Homeostatic model assessment (HOMA) 
Key points
• The prevalence of definite NASH histological criteria decreases in advanced liver disease, 
precluding these subjects from receiving new therapeutic options.
• Patients with NASH and not- NASH specific inflammatory activity share similar clinical fea-
tures and prognosis, and they are different from those with simple steatosis.
• Most of the patients with significant fibrosis and cirrhosis without a well- defined NASH show 
metabolic disturbances.
• This is the first study in clinical practice reinforcing the renaming of MAFLD.
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was calculated based on insulin and glucose (fasting insulin (mIU/
ml) × fasting glucose (mg/ml)/405).
We defined the following metabolic risk factors at baseline17: 
(a) type 2 diabetes mellitus (T2DM), defined by fasting blood 
glucose ≥126 mg/dl, or Hb1Ac >6.5%, or use of blood glucose- 
lowering agents; (b) arterial hypertension (AHT), determined by 
blood pressure ≥130/85 mm Hg or use of blood pressure- lowering 
agents; (c) low HDL, defined by HDL- c < 40 mg/dl in men or 
<50 mg/dl in women or use of lipid- lowering agents; (d) hyper-
triglyceridemia, characterized by triglyceride levels ≥150 mg/dl 
or use of lipid- lowering agents; (e) overweight and obesity, de-
termined by a body mass index (BMI) >25 and 30 kg/m2, respec-
tively; (f) insulin resistance, defined by HOMA > 2.5 in absence of 
T2DM. Metabolic syndrome was considered when at least three 
single components were present, while MAFLD was defined ac-
cording to the recent consensus.3
Follow- up was defined, depending on the endpoint, as the 
time from the liver biopsy to the progression to cirrhosis (for non- 
cirrhotic patients), the first event of cirrhosis complication (asci-
tes, hepatic encephalopathy and variceal bleeding) or death. They 
were collected whenever the investigator received notice about 
the event. In the case of no event, patients were censored at 
10 years of follow- up or at the end of the study period (May 2020). 
In non- cirrhotic patients at baseline, the progression to cirrhosis 
was considered when typical findings of cirrhosis were observed 
during the follow- up in a second liver biopsy (3/90), abdominal ul-
trasound (38/90) or transient elastography (>16 kPa) (36/90), or 
when an episode of decompensated cirrhosis occurred (13/90) 
(TARGET- NASH criteria18).
2.3 | Histological assessment
The diagnosis of NAFLD was based on histological criteria. All liver 
biopsies were assessed by experienced hepato- pathologists (leaded 
by MJPM), associated with the LITMUS histopathologists group,19 
who were blinded regarding the patient's evaluation and clinical 
data. Samples of <15- mm length or <10 portal tracts were consid-
ered not suitable for diagnosis and were excluded. Several histo-
logical aspects were measured. Steatosis, lobular inflammation and 
hepatocyte balloon degeneration were systematically assessed ac-
cording to the NASH CRN Scoring System: (a) Steatosis was rated as 
Grade 0 (<5%), Grade 1 (5%– 33%), Grade 2 (33%– 66%) and Grade 
3 (>66%); (b) hepatocyte ballooning was considered as 0 (none), 1 
(mild- few) and 2 (moderate- marked); (c) lobular inflammation was 
rated as 0 (none), 1 (<2 foci/20 optical field), 2 (2- 4 foci/20 optical field) 
and 3 (>4 foci/20 optical field). Although NASH CRN does not define 
exactly NASH by using the NAS score,20 we determined NASH ac-
cording to NAS score ≥4 (with at least 1 point each in inflammation 
and ballooning).7 This threshold was based on the inclusion criteria 
of most Food and Drug Administration (FDA)- approved clinical trials 
to develop NAFLD therapeutic drugs. The severity of fibrosis was 
staged from 0 to 4.
2.4 | Objectives
We assessed if NAS score ≥4 as inclusion criterion in NAFLD clinical 
trials reflects a reliable scenario in clinical practice, due to some cases 
with higher NAS score could not have findings of definite NASH and 
other cases of lower NAS score do.20 To achieve this goal, secondary 
aims were (a) to analyze the presence and the distribution of NAS 
score ≥4 and of its single components (steatosis, inflammation and 
ballooning) across the fibrosis stages; (b) to analyze the histological 
features of patients with apparent lack of NASH (NAS < 4), who are 
usually excluded from clinical trials; (c) to perform an exploratory 
analysis to determine the prognosis of three histological patterns 
based on NAS score and liver inflammation (NASH vs. indeterminate 
NASH vs. NAFL) in terms of progression to cirrhosis, the appearance 
of the first episode of decompensated cirrhosis and death.
2.5 | Statistical analyses
Data were reported as the mean ± standard deviation for normal 
and median (interquartile range) for non- normal continuous vari-
ables, while frequency was used for discrete variables. In the uni-
variate comparisons, we used the Student's t test and ANOVA with 
Bonferroni adjustments for continuous samples and chi- square test 
or Fisher's exact test for the qualitative ones. Non- parametric al-
ternatives (Mann– Whitney U and Kruskal– Wallis tests) were used 
for non- normal distributions. Survival analysis was assessed by the 
Kaplan– Meyer method, and differences between patient subgroups 
were evaluated by the log- rank test. Values were supposed to be 
statistically significant when P < .05.
On the other hand, the annual rate of progression to cirrhosis 
and the appearance of the first episode of decompensated cirrhosis 
and death were computed by dividing the number of patients with 
the defined event by the number of person years of which patients 
were followed. We multiply rates by 100 to transform in cases per 
100 person years.
The method used for missing data was complete- case analysis 
because statistical packages excluded individuals with any missing 
value. STATA (12.0, STATA Corporation, College Station, TX, USA) 
statistical package was used in all analyses and GraphPad Prism (ver-
sion 6.0; GraphPad Software, Inc, La Jolla, CA) for graphics.
3  | RESULTS
3.1 | Baseline features of the study population
The baseline features of the study cohort are stated in Tables 1 
and S1. Briefly, steatohepatitis (NAS ≥ 4) was present in 51.9% 
(982/1893) of the overall population. According to liver fibrosis: F0 
34.3% (649/1893), F1 27% (511/1893), F2 16.5% (312/1893), F3 
15% (284/1893) and F4 7.2% (137/1893). The 41.6% (788/1893), 
36.8% (696/1893) and 21.6% (409/1893) showed Grades 1, 2 and 
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3 of steatosis, respectively. On the other hand, lobular inflammation 
was seen in 73.5% (1391/1893) of patients (50.5% had mild and 23% 
moderate- to- severe inflammation), while ballooning was present in 
67% (1269/1893) of subjects (47.6% showed mild- few and 19.4% 
moderate- marked). The histological activity in patients, stratified by 
fibrosis stage, is shown in Table 2.
3.2 | Histological features depending on the 
fibrosis stage
We analyzed the distribution of severe steatosis (Grade 3), bal-
looning and lobular inflammation according to the fibrosis stage 
(Figure 1A). All these three single components of the histological 
definition of steatohepatitis were less frequent in patients with F0. 
The prevalence of these features, according to the fibrosis stage, 
showed an inverted U- shaped curve. Particularly, severe steatosis, 
ballooning and lobular inflammation increased from F1 to F2, while 
their percentage was similar in F3 and decreased in F4 patients. 
According to the NAS score, the same trend was observed for the 
distribution of NASH- specific inflammation, which was significantly 
lower in cirrhotic than in F2 and F3 patients (Figure 1B). Besides, we 
analyzed the distribution of the following histological patterns by 
fibrosis stage: steatohepatitis (NAS ≥ 4) versus indeterminate NASH 
(at least, presence of ballooning or lobular inflammation) versus 
NAFL (lack of ballooning and lobular inflammation); in the overall co-
hort (Figure 2A) and depending on the presence of diabetes mellitus 
(Figure 2B), obesity (BMI > 30) (Figure 2C), the indication of the liver 
biopsy (Figure 2D) and the sex (Figure 2E).
On the other hand, the distribution of steatohepatitis, as well as 
their individual components, is shown in Table S2, according to the 
presence of MAFLD clinical criteria. Briefly, the presence of meta-
bolic derangement influenced a higher inflammatory activity in the 
liver only in patients with F0: ballooning 51.6% versus 22.5%, lobu-
lar inflammation 57.5% versus 32.5% and NASH 35% versus 12.5% 
(P < .05 for all comparisons).




Male sex 48% (909/1893)
Age; years ± SD 51.8 ± 12.3
BMI ± SD (kg/m2) 35.3 ± 8.8
Obesity (BMI > 30 kg/m2) 61.5% (1164/1893)
Arterial hypertension 48.7% (922/1893)
Type 2 diabetes mellitus 36.7% (695/1893)
Glucose ± SD (mg/dl) 118 ± 43
HOMA- IR ± SD 5.5 ± 5.2
HOMA > 2.5 (in absence of T2DM) 14.4% (273/1893)
Total cholesterol ± SD (mg/dl) 194 ± 45
HDL- c ± SD (mg/dl) 49 ± 15
LDL- c ± SD (mg/dl) 117 ± 38
Triglycerides ± SD (mg/dl) 166 ± 116
Hypertriglyceridemia 48.1% (910/1893)
AST ± SD (IU/L) 43 ± 38
ALT ± SD (IU/L) 60 ± 53
GGT ± SD (IU/L) 102 ± 57
Phosphatase alkaline ±SD (IU/L) 95 ± 53
Bilirubin ± SD (mg/dl) 0.68 ± 0.4
Albumin ± SD (g/dl) 4.39 ± 0.4
Creatinine ± SD (mg/dl) 0.83 ± 0.2
Platelet count ± SD (×109/L) 234 ± 71
INR ± SD 1.03 ± 0.1
Abbreviations: BMI, body mass index; SD, standard deviation.
TA B L E  2   Histological activity, including steatohepatitis, steatosis, ballooning and lobular inflammation, stratified by fibrosis stage
Fibrosis stage F0 F1 F2 F3 F4
NASH (NAS > 4) 33.6% (218/649) 56.2% (287/511) 68.6% (214/312) 67.6% (192/284) 51.8% (71/137)
Steatosis
Grade 1 50.5% (328/649) 37.4% (191/511) 34.3% (107/312) 34.9% (99/284) 46% (63/137)
Grade 2 34.4% (191/649) 38.7% (198/511) 36.2% (113/312) 39.8% (113/284) 35.8% (49/137)
Grade 3 15.1% (98/649) 23.9% (122/511) 29.5% (92/312) 25.4% (72/284) 18.2% (25/137)
Ballooning
0 50.2% (326/649) 25.2% (129/511) 18.6% (58/312) 23.2% (66/284) 32.8% (45/137)
1 39% (253/649) 54% (276/511) 51% (159/312) 52.5% (149/284) 46.7% (64/137)
2 10.8% (73/649) 20.7% (106/511) 30.4% (95/312) 24.3% (69/284) 20.4% (28/137)
Lobular inflammation
0 44.1% (286/649) 20.9% (107/511) 11.9% (37/312) 15.1% (43/284) 21.2% (29/137)
1 43.8% (284/649) 56.2% (287/511) 53.5% (167/312) 51.4% (146/284) 52.6% (72/137)
2 10.3% (67/649) 18.6% (95/511) 28.8% (90/312) 30.3% (86/284) 22.6% (31/137)
3 1.8% (12/649) 4.3% (22/511) 5.8% (18/312) 3.2% (9/284) 3.6% (5/137)
Abbreviation: NASH, nonalcoholic steatohepatitis.
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F I G U R E  1   Histological features depending on the fibrosis stage. A, Prevalence of severe steatosis (Grade 3)*, ballooning (>1)**, and 
lobular inflammation (>1)***. B, NAS score. *P values for steatosis. F0 versus F4 0.356; F1 versus F4 0.162; F2 versus F4 0.012; F3 versus F4 
0.104. **P values for ballooning. F0 versus F4 0.0002; F1 versus F4 0.074; F2 versus F4 0.0009; F3 versus F4 0.036. ***P values for inflammation. 
F0 versus F4 <0.0001; F1 versus F4 0.953; F2 versus F4 0.010; F3 versus F4 0.036
F I G U R E  2   Distribution of definite nonalcoholic steatohepatitis (NASH), indeterminate NASH, and nonalcoholic fatty liver (NAFL). A, 
Overall cohort. B, Depending on the presence of type 2 diabetes mellitus (T2DM). C, Depending on the presence of obesity. D, Indication of 
the liver biopsy. E, Comparison between men and women
(A) (B) (C)
(D) (E)
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3.3 | Histological features in patients without NASH
Despite 31.4% of patients showing F2 had no NASH, 83.7% of 
these patients showed some inflammatory component (ballooning 
or lobular inflammation) in the liver biopsy (Figure 3A). Also, a third 
of patients with advanced fibrosis were not diagnosed with NASH. 
However, up to 71.7% of them showed some inflammatory degree in 
the liver (Figure 3B). In cirrhotic patients, the percentage of patients 
without steatohepatitis was 48.2%, although up to 68.2% of them 
showed at least ballooning or lobular inflammation (Figure 3C).
3.4 | Baseline features according to the 
histological pattern
According to the histological pattern, the baseline features of the 
overall population are shown in Table 3. Briefly, both NASH and in-
determinate NASH groups showed similar rates for metabolic factors 
such as obesity, diabetes mellitus and arterial hypertension, as well 
as they were not significantly different for liver tests like bilirubin, 
albumin or platelet levels. Instead, NASH patients showed signifi-
cantly higher AST and ALT levels. Also, MAFLD criteria were pre-
sent in 96.2% (945/982) of NASH patients and 95.2% (535/562) in 
indeterminate NASH, while it was 89.1% (311/349) in patients with 
NAFL (P < .0001). On the other hand, the distribution of MAFLD by 
histological pattern and fibrosis stage is shown in Figure S1.
3.5 | Prognosis according to the histological pattern
After the exclusion of patients who underwent liver biopsy during 
bariatric surgery (n = 539) and were enrolled in clinical trials (n = 120), 
1234 subjects (65.2% of the overall cohort) were included in the sur-
vival analysis. During the follow- up (mean time 4.7 ± 3.8 years), 2.8% 
(34/1234) of patients died, 1.9% (24/1234) suffered from a first de-
compensation (10.3% (12/116) among baseline cirrhotic patients), 
8.1% (90/1118) of non- cirrhotics suffered progression to cirrhosis 
and 1.1% (13/1234) developed hepatocellular carcinoma.
Fibrosis stage was the main histological determinant on the 
prognosis of the overall cohort (mortality was F0 1.8% [7/392] vs. 
F1 1.6% [5/315] vs. F2 3.1% [6/196] vs. F3 2.8% [6/215] vs. F4 9.6% 
[10/116]; logRank 22.369, P = .0001). On the other hand, despite 
having more patients with advanced liver disease, NASH patients 
had not a worse survival (2.7% [16/598]) than those with inde-
terminate NASH (1.4% [5/355]) or NAFL (4.6% [13/281]) (logRank 
3.175; P = .204). Also, the three groups suffered a similar rate 
of first cirrhosis decompensation during the study (2% [12/598] 
vs. 1.7% [6/355] vs. 2.1% [6/281]; P = .806). Nevertheless, the 
incidence of progression to cirrhosis was significantly higher for 
both NASH patients (9.5% [51/539]; HR 2.35 [95% CI 1.30- 4.26]) 
and those with indeterminate NASH (7.9% [25/316]; HR 1.90 
[95% CI 1.01- 3.66] [p = ns between them]) compared to subjects 
with NAFL (5% [14/263]; HR 1.00 [reference]) (logRank 8.417; 
P = .015) (Figure 4A). Consequently, the annual incidence rate of 
F I G U R E  3   Histological features in patients without a definite nonalcoholic steatohepatitis (NASH) diagnosis. A, Significant fibrosis. B, 
Advanced fibrosis. C, Cirrhosis
31.4%68.6%
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progression to cirrhosis was higher for patients with NASH and 
indeterminate NASH than those with NAFL (Figure 4B).
On the other hand, the impact of the histological pattern on 
both mortality and decompensated cirrhosis was not influenced by 
MAFLD despite showing higher percentages of these outcomes in 
dysmetabolic patients (P > .05). According to progression to cirrho-
sis, MAFLD also did not modify the impact of patients with NASH 
or indeterminate NASH. By contrast, patients showing NAFL and 
MAFLD showed higher progression to cirrhosis than those metabol-
ically healthy patients (6.1% [14/231] vs. 0% [0/32]; logRank 3.677, 
P = .049) (Figure 4C).
4  | DISCUSSION
Our study observed that the prevalence of NASH, defined by 
NAS ≥ 4 (with at least 1 point each in inflammation and ballooning), 
decreased in advanced liver disease, particularly in cirrhotic patients. 
Also, more than 70% of patients with NAS < 4 showed some inflam-
matory degree in the liver biopsy. Both NASH and indeterminate 
NASH patients shared a similar rate of metabolic risk factors (in-
cluding obesity, diabetes, arterial hypertension and dyslipidemia) 
and liver tests (albumin, bilirubin and platelets), although those with 
NAS ≥ 4 presented higher levels of AST and ALT. Besides, these sub-
groups showed a significantly higher proportion of MAFLD criterion 
than simple steatosis, focusing this term on patients with a higher 
likelihood of some hepatic inflammatory grade. Interestingly, both 
NASH and indeterminate NASH showed similar progression rates 
to cirrhosis, decompensated cirrhosis and mortality. Therefore, our 
findings cast doubt on current selection criteria for clinical trials 
because many subjects, who would benefit from an experimental 
treatment to halt the progression of the liver disease, could be ex-
cluded from clinical trials due to the absence of one single compo-
nent of definite NASH.
A relatively high proportion of our patients did not show find-
ings related to definite NASH (notably, half of the cirrhotic patients 
and a third of those with advanced fibrosis could not be diagnosed 
from NASH). A recent Italian study demonstrated that up to 33% of 
patients with NAFLD- related significant fibrosis did not show NASH 
(up to 10% had no inflammation), although the authors did not assess 




P value for the 
trend
Male sex 44.6% (438/982)a,b  51.6% (290/562) 51.9% (181/349) .008
Age; years ± SD 51.9 ± 12.4 52.1 ± 12.4 50.8 ± 11.9 .243
BMI ± SD (kg/m2) 35.9 ± 8.7a  35.2 ± 8.7 34 ± 9 .005
Obesity (BMI ≥30 kg/m2) 70.9% (640/903)a  67.5% (349/517)c  59.7% (175/293) .002
Arterial hypertension 51.8% (515/982)a  48.2% (271/562)c  40.7% (142/349) .002
Type 2 diabetes mellitus 40.4% (397/982)a  37.4% (210/562)c  25.2% (88/349) .0001
Glucose ± SD (mg/dl) 121 ± 44a  117 ± 46 112 ± 37 .005
HbA1c (%) 6.5 ± 1.5a  6.4 ± 1.4c  6 ± 1.3 .017
Total cholesterol ± SD (mg/dl) 194 ± 47 193 ± 44 194 ± 43 .913
HDL- c ± SD (mg/dl) 48 ± 15b  51 ± 17 49 ± 13 .003
LDL- c ± SD (mg/dl) 116 ± 39 118 ± 37 120 ± 36 .346
Triglycerides ± SD (mg/dl) 177 ± 120a,b  160 ± 125 147 ± 75 .0001
Hypertriglyceridemia 53% (520/982)a,b  46.3% (260/562)c  37.2% (130/349) .0001
AST ± SD (IU/L) 48 ± 46a,b  38 ± 25 36 ± 28 .0001
ALT ± SD (IU/L) 67 ± 61a,b  53 ± 40 54 ± 46 .0001
Bilirubin ± SD (mg/dl) 0.67 ± 0.4 0.70 ± 0.4 0.70 ± 0.4 .252
Albumin ± SD (g/dl) 4.39 ± 0.4 4.37 ± 0.5 4.41 ± 0.4 .520
Creatinine ± SD (mg/dl) 0.82 ± 0.3 0.83 ± 0.2 0.83 ± 0.2 .682
Platelet count ± SD (×109/L) 233 ± 70 231 ± 71 240 ± 74 .209
INR ± SD 1.03 ± 0.1 1.04 ± 0.2 1.03 ± 0.2 .830
MAFLD criteria 96.2% (945/982)a  95.2% (535/562)c  89.1% (311/349) .0001
Cirrhosis 7.2% (71/982) 8% (45/562) 6% (21/349) .530
Abbreviations: BMI, body mass index; MAFLD, metabolic- associated fatty liver disease; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic 
steatohepatitis; SD, standard deviation.
ap<0.05 for comparison between NASH and indetermined NASH.
bp<0.05 for comparison between NASH and NAFL.
cp<0.05 for comparison between indetermined NASH and NAFL.
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the distribution of NAS single components across the different fi-
brosis stages.21 Another French study defined histologically severe 
disease as a SAF activity score ≥3 or advanced fibrosis (not requir-
ing steatohepatitis), assuming that patients with NAFLD- related 
advanced liver disease could not have some definite elements of 
NASH.22 Besides, steatofibrosis demonstrated to have higher overall 
mortality than NASH in NAFLD patients.23
Interestingly, despite the lack of a definite NASH diagnosis, 
most of the patients included in our study showed some inflam-
matory degree in the liver biopsy, irrespective of the fibrosis stage. 
Indeterminate NASH, a subclassification recognized by the NASH 
CRN system, is characterized by steatosis with inflammation and 
hepatocyte injury but atypical of definite steatohepatitis, and it 
can be associated with varying amounts of fibrosis.5 It has been 
documented that fibrosis can progress even in patients without 
baseline steatohepatitis features, due to ballooning and lobular in-
flammation predicted fibrosis progression.24 Consequently, these 
patients would more likely develop complications and should be 
cautiously monitored. In this scenario, we observed that both 
patients with NASH and indeterminate NASH showed similar 
F I G U R E  4   A, Kaplan– Meier curve to show the impact of the histological pattern on the progression to cirrhosis. B, Annual incidence 
rate of progression to cirrhosis depending on histological pattern and fibrosis stage (cases per 100 person- years). C, Kaplan– Meier curve to 
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progression rates to cirrhosis, decompensated cirrhosis and mor-
tality. These findings would support the concept of burn- out in 
NASH- related cirrhosis.25
Indeterminate NASH, irrespective of fibrosis stage, belongs to the 
subpopulation of non- NASH, similar to NAFL, according to the Case 
Definitions Working Group.5 Consequently, some scenarios could not 
contemplate this entity as the main etiology of liver disease. We ob-
served a similar clinical phenotype between NASH and indeterminate 
NASH patients, including the presence of metabolic factors (MAFLD 
was shown by more than 95% for the two groups) and liver tests (eg, al-
bumin and bilirubin). An integral diagnosis, including histological crite-
ria and metabolic risk factors, could avoid the diagnosis of cryptogenic 
liver disease in a significant number of individuals.26 Most importantly, 
it could help to decrease screening failures in clinical trials and avoid 
wasting the opportunity of useful therapy in patients at risk of pro-
gression.27 Besides, considering the clinical phenotype to define the 
origin of liver cirrhosis in some circumstances would have two signifi-
cant benefits. First, knowing the etiology of cirrhosis is mandatory for 
personalized counselling and management. For instance, in the liver 
transplant, immunosuppressive approach, monitoring of extrahepatic 
events and the likelihood of recurrence could change depending on 
the etiology. Second, patients suffer from anxiety and frustration and 
have many future uncertainties when they are diagnosed with a lead-
ing cause of mortality, such as cirrhosis, but they have no explanations 
about how the disease appeared and how they have to proceed.28,29 
For instance, primary biliary cirrhosis has been renamed to cholangitis 
owing to these reasons.30
The study has some limitations usually observed when real- 
world data are evaluated. Ideally, the biopsies of all patients should 
be assessed by one single pathologist to avoid introducing some 
interobserver variability. Besides, the sampling variability of the bi-
opsies might explain part of the findings. Despite these concerns, 
the results were consistent and robust after analyzing the data cen-
tre by centre (in fact, almost half of the cohort was reviewed by a 
single central pathologist - MJPM- ). Probably, the fact of having a 
very selected group of expert hepato- pathologists who review all 
the biopsies after an initial discussion to homogenizes the interpre-
tation of histologic criteria19 and that patients whose samples are 
not suitable for diagnosis are excluded from Hepamet Registry could 
mitigate the worries. Also, a mean follow- up time of 4.7 years could 
not be enough to observe a high number of prognostic outcomes (eg, 
hepatocellular carcinoma). However, we performed an exploratory 
analysis in which we found statistically significant differences for 
cirrhosis progression, probably because there were fast progressors, 
including the use of annual incidence rate that considers for subjects 
the actual time at risk and does not require to complete the total 
follow- up time.
In summary, steatohepatitis features seem to be absent in half 
of the patients with significant fibrosis and cirrhosis, which could 
increase the screening failure rates and preclude to receive new 
therapeutic options in a subset of patients at high risk of progres-
sion and extrahepatic and/or liver- related outcomes. Future studies 
should individualize the most appropriate criteria for diagnosing and 
including patients in clinical trials according to the integration of clin-
ical and histological features due to the NAS score limitation for such 
purpose.
CONFLIC T OF INTERE S T
None.
AUTHOR CONTRIBUTIONS
Guarantor of the article: JA and MRG. Study design: JA. Drafting the 
manuscript: JA and MRG. Statistical analyses and interpretation: JA 
and MRG. Data acquisition and critical review of the manuscript: All 
authors. All authors approved the final version of the article, includ-
ing the authorship list.
ORCID
Javier Ampuero  https://orcid.org/0000-0002-8332-2122 
Rocío Gallego- Durán  https://orcid.org/0000-0002-9452-1661 
Águeda González- Rodríguez  https://orcid.org/0000-0001-6428-6210 
Germán Soriano  https://orcid.org/0000-0002-9267-6811 
Raúl J. Andrade  https://orcid.org/0000-0002-1565-0757 
Jesús M. Banales  https://orcid.org/0000-0002-5224-2373 
Salvador Benlloch  https://orcid.org/0000-0002-0794-6937 
R E FE R E N C E S
 1. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalco-
holic steatohepatitis. N Engl J Med. 2017;377:2063- 2072.
 2. Burt AD, Lackner C, Tiniakos DG. Diagnosis and assessment of 
NAFLD: definitions and histopathological classification. Semin Liver 
Dis. 2015;35:207- 220.
 3. Eslam M, Sanyal AJ, George J. an international consensus panel. 
MAFLD: a consensus- driven proposed nomenclature for metabolic 
associated fatty liver disease. Gastroenterology. 2020;158(7):1999- 
2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312
 4. Ampuero J, Aller R, Gallego- Durán R, et al. The effects of met-
abolic status on non- alcoholic fatty liver disease- related out-
comes, beyond the presence of obesity. Aliment Pharmacol Ther. 
2018;48:1260- 1270.
 5. Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Case definitions for 
inclusion and analysis of endpoints in clinical trials for nonalcoholic 
steatohepatitis through the lens of regulatory science. Hepatology. 
2018;67:2001- 2012.
 6. Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability 
of liver biopsy evaluation has implications for randomized clinical 
trials. J Hepatol. 2020;73(6):1322- 1332. https://doi.org/10.1016/j.
jhep.2020.06.025
 7. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation 
of a histological scoring system for nonalcoholic fatty liver disease. 
Hepatology. 2005;41:1313- 1321.
 8. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selon-
sertib in patients with nonalcoholic steatohepatitis: A randomized, 
phase 2 trial. Hepatology. 2018;67:549- 559.
 9. Pai RK, Kleiner DE, Hart J, et al. Standardising the interpretation 
of liver biopsies in non- alcoholic fatty liver disease clinical trials. 
Aliment Pharmacol Ther. 2019;50:1100- 1111.
 10. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibro-
sis stage in nonalcoholic fatty liver disease: Systematic review and 
meta- analysis. Hepatology. 2017;65:1557- 1565.
2086  |     AMPUERO Et Al
 11. Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/
EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 
2019;71:823- 833.
 12. Bedossa P. Diagnosis of non- alcoholic fatty liver disease/non- 
alcoholic steatohepatitis: why liver biopsy is essential. Liver 
International. 2018;38:64- 66.
 13. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive 
markers of fibrosis in patients with nonalcoholic fatty liver disease. 
Clin Gastroenterol Hepatol. 2009;7:1104- 1112.
 14. Castera L, Friedrich- Rust M, Loomba R. Noninvasive assessment 
of liver disease in patients with nonalcoholic fatty liver disease. 
Gastroenterology. 2019;156(5):1264- 1281.e4.
 15. Ampuero J, Pais R, Aller R, et al. Development and validation of 
hepamet fibrosis scoring system a simple, noninvasive test to iden-
tify patients with nonalcoholic fatty liver disease with advanced 
fibrosis. Clin Gastroenterol Hepatol. 2020;18(1):216- 225.e5. https://
doi.org/10.1016/j.cgh.2019.05.051
 16. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: 
a noninvasive system that identifies liver fibrosis in patients with 
NAFLD. Hepatology. 2007;45:846- 854.
 17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and manage-
ment of the metabolic syndrome: an American Heart Association/
National Heart, Lung, and blood institute scientific statement. 
Circulation. 2005;112:2735- 2752.
 18. Barritt AS, Gitlin N, Klein S, et al. Design and rationale for a real- 
world observational cohort of patients with nonalcoholic fatty 
liver disease: The TARGET- NASH study. Contemp Clin Trials. 
2017;61:33- 38.
 19. Hardy T, Wonders K, Younes R, et al. The European NAFLD 
Registry: a real- world longitudinal cohort study of nonalcoholic 
fatty liver disease. Contemp Clin Trials. 2020;98:106175.
 20. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander- Tetri BA. 
Nonalcoholic fatty liver disease (NAFLD) activity score and the his-
topathologic diagnosis in NAFLD: Distinct clinicopathologic mean-
ings. Hepatology. 2011;53:810- 820.
 21. Pelusi S, Cespiati A, Rametta R, et al. Prevalence and risk factors of 
significant fibrosis in patients with nonalcoholic fatty liver with-
out steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(11):2310- 
2319.e6.
 22. Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the 
FLIP algorithm and the SAF score in patients with non- alcoholic 
fatty liver disease. J Hepatol. 2020;72(5):828- 838. https://doi.
org/10.1016/j.jhep.2019.12.008
 23. Younossi ZM, Stepanova M, Rafiq N, et al. Nonalcoholic steatofi-
brosis independently predicts mortality in nonalcoholic fatty liver 
disease. Hepatol Commun. 2017;1:421- 428.
 24. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of fol-
low- up biopsies reveals disease progression in patients with non- 
alcoholic fatty liver. J Hepatol. 2013;59:550- 556.
 25. Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic steatohep-
atitis: cirrhosis, hepatocellular carcinoma, and burnt- out NASH. J 
Gastroenterol. 2004;39:1215- 1218.
 26. Younossi Z, Stepanova M, Sanyal AJ, et al. The conundrum of cryp-
togenic cirrhosis: adverse outcomes without treatment options. J 
Hepatol. 2018;69:1365- 1370.
 27. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver dis-
eases in the world. J Hepatol. 2019;70:151- 171.
 28. Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: 
an international patient perspective. Lancet Gastroenterol Hepatol. 
2021;6(1):73- 79. https://doi.org/10.1016/S2468 - 1253(20)30294 - 6
 29. Kimbell B, Boyd K, Kendall M, Iredale J, Murray SA. Managing un-
certainty in advanced liver disease: a qualitative, multiperspective, 
serial interview study. BMJ Open. 2015;5:e009241.
 30. Beuers U, Gershwin ME, Gish RG, et al. Changing nomencla-
ture for PBC: from “Cirrhosis” to “Cholangitis”. Gastroenterology. 
2015;149:1627- 1629.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Ampuero J, Aller R, Gallego- Durán R, 
et al; HEPAmet Registry. Definite and indeterminate 
nonalcoholic steatohepatitis share similar clinical features and 
prognosis: A longitudinal study of 1893 biopsy- proven 
nonalcoholic fatty liver disease subjects. Liver Int. 
2021;41:2076– 2086. https://doi.org/10.1111/liv.14898
